Investing In LPPFusion
During our Wefunder capital campaign anyone, anywhere in the world, can invest in LPPFusion, with a $1,000 minimum. The campaign will end March 1, 2020.
Accredited investors can invest through our Regulation D, 506 c offering, contained in our Private Placement Memorandum. This can be obtained by sending an email to email@example.com. You are an accredited investor if you can show a net worth of $1M or $200K annual earnings. If you are not accredited and are not on our mailing lists, watch for possible future equity crowdfunding announcements on our social media or sign up for a newsletter at the bottom of the page.
LPPFusion is a privately-held “C” corporation, incorporated in NJ in 2003. Prior to that, it was founded in Lawrenceville, NJ in 1984 by Eric Lerner – thus the L in LPP that stands for Lawrenceville Plasma Physics. We are doing business as LPPFusion however for simplicity reasons.
Australian Patent 2007314648 issued November 2011
Chinese patent, 200780007065.7 issued December, 2012
Canadian Patent, 2,642,749 issued December, 2015
European Union Patent EP 1989714B1 issued April, 2018
Still pending in India.
See our team page.
Since conducting initial experiments with $300K from NASA’s Jet Propulsion Laboratory, LPPFusion has raised over $7M from over 500 private investors from around the world, and institutional investment from the Abell Foundation of Baltimore, MD. Accredited U.S. and foreign investors can purchase Class B, non-voting shares.
We have successfully closed five previous equity rounds. Our current round will fund the upgrades to our Focus Fusion device and allow us to develop our spin-off X-scan technology for the market.
Investments in LPPFusion can be made by foreign and accredited U.S. investors (e.g. investors with net worth in excess of $1M, or income exceeding $200K), as defined in Rule 506(c) of Regulation D promulgated under the Securities Act of 1933, to purchase shares of Class B nonvoting stock of the Corporation (the “Offering”) to finance ongoing experimental efforts. Sales of shares pursuant to the Offering will only be made to accredited foreign and U.S. investors.
The securities in this Offering have not been registered with or approved by any state securities agency or the U.S. Securities and Exchange Commission and are being offered and sold pursuant to an exemption from registration. No money or other consideration is being solicited or will be accepted by way of this announcement.
If you are an accredited investor and would like additional information regarding this Offering, please contact us here.
LPPFusion Advisory to investors and potential investors
Based on extensive discussions and a vote of the Board of Advisors, and with the agreement of LPPFusion President Eric Lerner LPPFusion, Inc. issues the following advisory to investors and potential investors on future changes in LPPFusion share valuation.
As soon as our experiments with Focus Fusion device achieve 1 joule of fusion energy output, LPPFusion will immediately end the current share offering at $125/share and will issue a new offering at $150/share. As soon as Focus Fusion device achieves 10 joules of fusion energy output, LPPFusion will immediately end the existing share offering and issue a new offering at $200/share.
This increase in valuation is in line with our past share price increases when Focus Fusion device produced good initial results after construction and also when it produced record temperature levels. As progress continues toward our goal of net energy output, the higher valuations will reflect the risk/reward level at that time.
Financial Audit Reports
. . . . .
This web page is not intended to be an offer of securities to the residents of any state, nor is it an offer otherwise specifically directed to any person in any state by, or on behalf of, Lawrenceville Plasma Physics, Inc DBA LPPFusion. Any forward-looking statements are based on the beliefs of LPPFusion’s management and reflect current expectations at the time the statements are made with respect to future events based on information available at that time, and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in those forward-looking statements.